English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Schizophrenia is one of the most relevant mental disorders in public health, causing great distress for the patient and his/her family members. The persistence of symptoms characterizes refractoriness of the disease that is treated with clozapine considered the gold standard in treatment, but its adverse reactions can be as intense as the symptoms of the disorder. Objective: To develop a pharmacotherapeutic follow-up form for caregivers of adult patients with schizophrenia would refract from the use of clozapine. Methods: The search for the articles was carried out in the government databases and websites from November 15, 2018 to January 15, 2019, published from 2012. Result: Thirty-seven articles were found, excluding 20 articles, including in this review 17 articles, 2 books, 4 clinical protocols and 1 drug monograph. Conclusion: The proposal to develop the pharmacotherapeutic follow-up form is to identify adverse reactions that may influence the treatment of pharmacological treatment and reduce the unwanted effects of treatment as a consequence to improve the patient's quality of life.

Pharmacotherapeutic follow-up form for caregivers of patients with refractory schizophrenia